Prometco Interactive

PROMETCO: Real-world characteristics and safety outcomes of patients with metastatic colorectal cancer (mCRC) after two disease progressions, including patients with an ECOG PS ≥2

Data presented at the ESMO Gastrointestinal Cancers Congress 2025

Rocío García-Carbonero,¹ Jean-Baptiste Bachet,² Carmine Pinto,³ György Bodoky,⁴ Kalena Martí,⁵ Andrey Mitroshkin,⁶ Tomáš Büchler,⁷ Patrick Stuebs,⁸ Ana María López Muñoz,⁹ Rakesh Raman,¹⁰ Elias Choucair,¹¹ Bénédicte Chevallier,¹¹ Jessica Azzi,¹² Adam Sullivan,¹³ Miriam Koopman¹⁴

1. Oncology Department, Hospital Universitario Doce de Octubre, Imas12, Facultad y Departamento de Medicina, Universidad Complutense de Madrid (UCM), Avenida De Córdoba s/n, 28041 Madrid, Spain; 2. Sorbonne Université, Service d’hépato-Gastro-Entérologie, Groupe Hospitalier Pitié Salpêtrière, APHP, Paris, France; 3. Medical Oncology, Comprehensive Cancer Centre, AUSL – IRCCS di Reggio Emilia – Viale Risorgimento, 80 42123 Reggio Emilia, Italy; 4. Dél‑Pesti Centrumkórház Szent László Telephely Albert Flórián út 5–7 1097 Budapest, Hungary; 5. Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK; 6. Klinikum Freudenstadt, Akademisches Lehrkrankenhaus der Universität Tübingen, Karl-von-Hahn-Strasse, 100, 72250 Freudenstadt, Germany; 7. Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59 Prague, Czech Republic; 8. DRK Kliniken Berlin Köpenick, Salvador-Allende-Straße 2–8, 12559 Berlin; 9. Oncology Department, Hospital Universitario de Burgos, Avenida Islas Baleares 3, 09006. Burgos, Spain; 10. Kent Oncology Centre, Kent, UK; 11. Servier, 35 rue Verdun, 92284 Suresnes, France; 12. Institut de Recherches Internationales Servier, Gif-sur-Yvette, France; 13. Servier Pharmaceuticals, 200 Pier 4 Blvd, Boston, MA 02210, USA; 14. Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University Heidelberglaan 100 3584 CX Utrecht, Netherlands

PROMETCO: Study background and aim

Median OS for patients with metastatic colorectal cancer (mCRC) has been improved to 30 months in clinical trials.¹ Data suggest that third- or later line treatments, such as trifluridine/tipiracil (FTD/TPI) plus bevacizumab and fruquintinib, can extend OS even further^2,3
Data on real-world treatment of mCRC in third and later lines are available. However, studies with a follow-up of recruited patients were limited to specific agents or to a single country
PROMETCO (NCT03935763) is the first international, prospective, real-world study of treatment of patients with mCRC after two disease progressions since diagnosis

Aim: To assess safety outcomes at third- or later line treatment in the real-world setting

Inclusion criteria: Adults with two disease progressions since first diagnosis of mCRC, who were willing to receive subsequent treatment
Exclusion criteria: Patients enrolled in other clinical trials, receiving treatment for other cancers, or those with reduced mental capacity

At enrolment (March 2019), patient data were collected retrospectively using electronic case report forms and the ClinInfo electronic data capture system,⁴ and were assessed prospectively for up to 18 months or until withdrawal or death

Baseline characteristics (N=736)

Safety outcomes (N=736)

Conclusions

*ECOG PS score for 41 patients was not recorded.
^†Before FTD/TPI + bevacizumab was recognized as standard of care in third line.
ECOG PS, Eastern Cooperative Oncology Group performance status; FTD/TPI, trifluridine/tipiracil; mCRC, metastatic colorectal cancer; OS, overall survival.
1. Van Cutsem E, et al. Ann Oncol. 2016;27(8):1386–22. 2. Prager GW, et al. N Engl J Med. 2023;388(18):1657–67. 3. Dasari A, et al. Lancet. 2023;402(10395):41–53. 4. Koopman M, et al. Future Oncol. 2022;18(11):1313–20.